InnoSer News

InnoSer joins the Eurostars funded project ‘LEMONAID’

InnoSer joins the Eurostars funded project ‘LEMONAID’

LEMONAID takes on the challenge of developing a new drug against Diffuse Large B-Cell Lymphoma (DLBCL) tumors to ultimately reduce drug resistance and relapse potential for patients. InnoSer supports this ambition by its expertise in combined in-vitro and in-vivo...

InnoSer meets you at knowledge for growth event

InnoSer meets you at knowledge for growth event

Organized by flanders.bio since it's establishment in 2004, knowledge for growth brings over 1300 biotech, pharma, medtech, agricultural and chemical industry experts and decision makers, as well as investors, universities, topnotch research institutes, policymakers...

InnoSer welcomes Wim Tiest as its Chief Technology Officer

InnoSer welcomes Wim Tiest as its Chief Technology Officer

As of April 2020, Wim Tiest has joined InnoSer in the role of Chief Technology Officer (CTO) and as part of the company management team. Wim holds a MSc in biochemical engineering and in artificial intelligence, both from the KU Leuven. He has built his professional...

PDX/O oncology platform developments at InnoSer

PDX/O oncology platform developments at InnoSer

Despite the challenging times for the life sciences sector during coronavirus restrictions, we’ve been fortunate enough and well prepared to continue with the development of our PDX/O platform for oncology research. On a weekly basis we receive patient tumor samples...

Taking Precautions Against Coronavirus

Taking Precautions Against Coronavirus

Following the most recent governmental advice and regulations, we have decided to take preventative measures against the fast spread of COVID-19. The health and interests of our customers, employees and other stakeholders are our top priority. In order to minimize the...

InnoSer and TheraIndx Strategic Partnership

InnoSer and TheraIndx announce their strategic partnership to better serve pharmaceutical and biomedical companies worldwide. Jan Bartels, the CEO of InnoSer, states: “Both companies offer unique service portfolios and bring a lot of aligned added value to our global...

InnoSer gets new cell culture facilities

InnoSer is expanding its infrastructure to better its in vitro services. These specialized services include syngeneic oncology models, PBMC and immune population work in vitro/ex vivo, organoid culture, PDX passage work and any in vitro compound screening on fresh...

Interested In InnoSer’s Services?

Get in touch with us.